The current generation of multi-cancer early detection tests are not intended to be diagnostic; they are intended to ease and, hopefully, improve cancer screening efforts. Per the manufacturer, the Galleri test “is intended to be used in addition to and not replace other cancer screening tests.”
Explore This Issue
December 2022Multi-cancer early detection blood tests may aid in the detection of otherwise difficult-to-detect cancers. According to company literature, the Galleri test can detect a cancer signal “across more than 50 types of cancer, many of which are not commonly screened for today, “including oropharyngeal cancer, cancers of the nasal cavity and paranasal sinuses, and ovarian cancer. Available data suggest that the test has a positive predictive value of less than 50%.
Other companies and academic institutions are also working to develop blood-based cancer screening tests. “Researchers are looking at the efficacy and cost effectiveness of these tests,” Dr. Chang said. “The trials are ongoing.”